Lymphocyte Activation Gene-3 Blocker [EPC]

515 reported adverse events

Drugs of this class: NIVOLUMAB AND RELATLIMAB-RMBW

These side effects are most commonly reported by patients taking drugs of the Lymphocyte Activation Gene-3 Blocker [EPC] class:

# Side effect Count
0 DEATH 76
1 OFF LABEL USE 60
2 MALIGNANT NEOPLASM PROGRESSION 35
3 FATIGUE 19
4 MYOCARDITIS 19
5 PRODUCT STORAGE ERROR 19
6 PRODUCT DOSE OMISSION ISSUE 15
7 ADVERSE EVENT 13
8 COLITIS 13
9 RASH 13
See all common reactions for Lymphocyte Activation Gene-3 Blocker [EPC]

Drugs of the Lymphocyte Activation Gene-3 Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 AUTOIMMUNE ENDOCRINE DISORDER 1 0.0476
1 RADIATION RETINOPATHY 1 0.0435
2 METASTATIC OCULAR MELANOMA 1 0.0400
3 ASCARIASIS 1 0.0303
4 IMMUNE-MEDIATED CHOLESTASIS 1 0.0270
5 IMMUNE-MEDIATED GASTROINTESTINAL DISORDER 1 0.0233
6 BRAIN EMPYEMA 1 0.0179
7 VISCERAL VENOUS THROMBOSIS 1 0.0167
8 INTESTINAL MUCOSAL ATROPHY 1 0.0100
9 IMMUNE-MEDIATED MYASTHENIA GRAVIS 3 0.0092
See all enriched reactions for Lymphocyte Activation Gene-3 Blocker [EPC]